Home › Funds › ANTIPODES PARTNERS Ltd › BIIB

ANTIPODES PARTNERS Ltd position in BIIB

BIOGEN INC · Health Care

ANTIPODES PARTNERS Ltd reported holding 342,366 shares of BIIB (BIOGEN INC) in its Q3 2026 13F filing — a position valued at US$77.3M, representing 1.43% of its reported portfolio and ranking #35 among its reported holdings. ANTIPODES PARTNERS Ltd has disclosed BIIB holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

Latest position (Q3 2026)342.37K sh
Reported value held$77.33M
Portfolio Weight1.43%
First reportedQ2 2026
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How ANTIPODES PARTNERS Ltd's BIIB position evolved

ANTIPODES PARTNERS Ltd first disclosed a stake in BIIB in Q2 2026 at 86,827 shares (US$18.8M). The position peaked in Q3 2026 at 342,366 shares, worth US$77.3M. Across 2 filings, ANTIPODES PARTNERS Ltd increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 342,366 shares valued at US$77.3M — an increase of 255,539 shares quarter over quarter.. Notable position changes include a 294% increase in Q3 2026 (shares rose 12% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2026 86.83K $18.76M New
Q3 2026 342.37K $77.33M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BIIB and 13F data

BIIB (BIOGEN INC) is a Health Care company. 20 other funds we track also report a position in BIIB — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$3.43B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BIIB

All BIIB fund holders →

FAQ

How long has ANTIPODES PARTNERS Ltd held BIIB?

ANTIPODES PARTNERS Ltd has disclosed BIIB holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is ANTIPODES PARTNERS Ltd's current position in BIIB?

As of Q3 2026, ANTIPODES PARTNERS Ltd holds 342.37K shares of BIIB (BIOGEN INC), valued at $77.33M, representing 1.43% of its reported portfolio and ranking #35.

Has ANTIPODES PARTNERS Ltd been buying or selling BIIB?

In the latest 13F filing (Q3 2026), ANTIPODES PARTNERS Ltd increased its position in BIIB. The position peaked in Q3 2026 at 342.37K shares.

Which other funds hold BIIB?

Other major institutional holders of BIIB include PRIMECAP MANAGEMENT CO/CA/, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.